Soolantra and topical metronidazole are different prescription medicines used for inflammatory lesions of rosacea. Soolantra contains ivermectin 1% in a topical cream, whereas metronidazole is available in several topical products, including 0.75% cream and gel and 1% gel. The distinction matters when comparing pharmacy listings: the ingredients are not generic versions of one another, and the dosage form and concentration determine which label and clinical evidence apply. Both are intended for particular inflammatory manifestations of rosacea, not for every cause of facial redness or irritation.
The most directly relevant head-to-head evidence compared ivermectin 1% cream used once daily with metronidazole 0.75% cream used twice daily over 16 weeks in adults with moderate-to-severe papulopustular rosacea. In that study, the ivermectin group had a greater average reduction in inflammatory lesion counts. That is a meaningful research finding, but it does not prove that Soolantra is the best treatment for every person, that all metronidazole formulations perform alike, or that a patient will experience the same result. Clinical history, tolerance, the particular formulation and the treatment objective still matter.
For U.S. readers, the practical comparison also includes obtaining a valid prescription, identifying the exact product and understanding brand versus generic choices. Begin with the Soolantra brand overview for the specific ivermectin cream and the ivermectin cream 1% product guide for ingredient-level context. This page focuses on what is genuinely different between ivermectin and metronidazole, how to interpret the clinical comparison and which questions to clarify before a pharmacy fill. It does not replace a clinician’s diagnosis or prescribing decision.
The clearest comparison starts with the exact medicine rather than a broad claim that one “rosacea cream” is better. Soolantra is one branded ivermectin cream at a defined concentration. Metronidazole is a distinct active ingredient sold under branded and generic names in multiple topical forms. This table uses metronidazole 0.75% cream as the main comparator because that is the formulation evaluated in the frequently cited direct clinical trial; it identifies 1% gel separately to avoid mixing evidence across products.
Both product families are prescription topical treatments in the United States. Their labeled uses overlap in inflammatory rosacea, but differences in active ingredient, formulation, dosing directions, tolerability and individual history can affect a clinician’s choice. Pharmacy availability and out-of-pocket costs require separate verification and cannot be inferred from a research result.
| Comparison point | Soolantra (ivermectin cream 1%) | Topical metronidazole | Why the distinction matters |
|---|---|---|---|
| Active ingredient | Ivermectin | Metronidazole | They are different drugs, not brand and generic versions of the same medicine |
| Main product in direct trial | Ivermectin cream 1% | Metronidazole cream 0.75% | Clinical findings belong to these studied formulations |
| Other U.S. formulations | Generic ivermectin creams 1% also exist | Products include 0.75% cream, 0.75% gel/lotion and 1% gel | Do not assume every formulation was directly compared |
| Prescription status | Prescription (Rx) | Prescription (Rx) | A clinician assesses appropriateness before dispensing |
| Relevant labeled use | Inflammatory lesions of rosacea | Topical rosacea treatments have product-specific labels for inflammatory lesions | Neither should be described as a universal cure for flushing, redness or ocular symptoms |
| Labeled frequency for examples | Once daily for Soolantra cream 1% | 0.75% cream is commonly labeled twice daily; METROGEL 1% is labeled once daily | Follow the exact dispensed product label, not a generic online schedule |
| Direct trial comparison | Ivermectin 1% cream, once daily | Metronidazole 0.75% cream, twice daily | Research results cannot be generalized automatically to 1% gel |
| Brand and generic status | Soolantra brand plus approved generic ivermectin cream | Multiple branded and generic metronidazole topical products | Verify active ingredient, strength and dosage form on pharmacy labels |
| Formulation and excipients | Cream base and formulation-specific ingredients | Cream, gel or lotion bases vary by product | Base ingredients may influence how a product feels on sensitive skin |
| Cost and coverage | Brand versus generic, plan and pharmacy factors | Product type, generic options, plan and pharmacy factors | There is no reliable universal price ranking without a comparable quote |
Soolantra cream contains 1% ivermectin, equivalent to 10 mg of ivermectin in each gram of cream. It is a specifically labeled prescription product for treating inflammatory lesions of rosacea. Its product description and safety instructions concern the topical cream, not oral ivermectin tablets or OTC ivermectin lice lotion. To keep those forms separate, the topical ivermectin overview explains why identical ingredient names across different formulations do not make them interchangeable.
Metronidazole belongs to a different drug class and appears in several dermatologic products. Topical metronidazole has recognized anti-inflammatory effects in rosacea, although its complete mechanism in this condition is not fully established. In contrast, ivermectin’s clinical use is associated with anti-inflammatory activity and effects on Demodex mites, but a patient’s response cannot be predicted simply from the presence or absence of mites. Mechanistic differences are useful background, not a substitute for comparing the treatment evidence and the diagnosis.
Neither cream is a generic alternative to the other. A pharmacist cannot treat a request for Soolantra as equivalent to a request for metronidazole merely because both medicines can be prescribed for rosacea. A change between active ingredients is a treatment change requiring the appropriate prescribing authority and patient-specific clinical review. The direct brand-versus-generic question belongs to Soolantra versus generic ivermectin cream, where the compared products actually share the same active ingredient.
The term “topical metronidazole” can refer to more than one medicine listing. U.S. labels include metronidazole 0.75% cream, gel and lotion products, as well as metronidazole 1% gel. The concentration and vehicle should be read directly from the label, because a gel and an emollient cream may have different excipients, instructions and patient preferences. A pharmacy substitution or a comparison with another rosacea medicine should identify the product precisely rather than using only the ingredient name.
This matters particularly for dosing discussions. The well-known head-to-head study used metronidazole 0.75% cream twice daily, whereas the U.S. label for METROGEL 1% describes once-daily use. The comparison therefore does not establish that every metronidazole product requires two applications per day. Nor does the fact that Soolantra is labeled once daily show that a particular patient will find it easier to tolerate or use. The dispensed product’s instructions and clinician advice take precedence over general comparisons.
The vehicle can also be relevant when skin is dry, reactive or affected by other topical treatments. Sensory differences such as heaviness, drying or stinging vary across formulations and individuals; they should not be presented as universal properties of all ivermectin or metronidazole products. When evaluating a prescription, ask which concentration and vehicle the clinician intends, whether the pharmacy is dispensing the same form and how to handle concurrent skin-care products.
In a randomized, investigator-blinded trial enrolling 962 participants with moderate-to-severe papulopustular rosacea, 478 participants were assigned ivermectin 1% cream once daily and 484 were assigned metronidazole 0.75% cream twice daily. Over 16 weeks, the mean percentage reduction from baseline in inflammatory lesion count was 83.0% in the ivermectin group and 73.7% in the metronidazole group. These percentages describe average lesion-count changes during a defined study; they are not a probability that an individual will improve by that amount.
The same trial reported that 84.9% of patients treated with ivermectin and 75.4% treated with metronidazole were rated clear or almost clear on an investigator global assessment at week 16. This result supports a comparative efficacy advantage for ivermectin 1% cream over the specific 0.75% metronidazole cream regimen studied. It should not be rewritten as a guarantee of clearance, proof of superior performance against metronidazole 1% gel or evidence that every rosacea phenotype responds best to ivermectin.
Study design and endpoints matter. The trial enrolled people with inflammatory papules and pustules rather than a population defined solely by persistent redness, flushing, ocular symptoms or acne-like eruptions. Subsequent research has evaluated relapse and longer-term outcomes in selected responders, but those findings also reflect eligibility and follow-up conditions. Patients with different severity, prior-treatment histories or treatment tolerability may reasonably discuss either medicine with a clinician. Trial results help inform that discussion rather than prescribing a choice.
Rosacea is not a single uniform symptom. Many patients have some combination of inflammatory papules or pustules, persistent facial redness, episodes of flushing, visible small blood vessels and skin sensitivity. Soolantra and topical metronidazole are compared most meaningfully when inflammatory lesions are a major treatment target. Improvements in lesion counts should not be interpreted as proof that either medicine will eliminate every kind of facial redness or address ocular involvement.
The diagnosis also deserves attention. Ordinary acne, seborrheic dermatitis, contact dermatitis and perioral dermatitis can resemble aspects of rosacea, yet medication choice depends on the actual condition and its severity. Soolantra is not FDA-approved as a general acne cure, and a comparison with metronidazole should not be presented as an instruction to self-treat undiagnosed facial eruptions. Readers seeking a broader ingredient perspective can visit ivermectin and rosacea for condition context without changing this page’s head-to-head focus.
A clinician may consider how much inflammation is present, which products have already been tried, whether the skin is unusually reactive and what additional treatments are needed. Those factors are more useful than assuming that a higher percentage in one trial establishes a universal hierarchy. Persistent or worsening symptoms merit reassessment rather than repeated unsupervised switching between prescriptions.
Both topical treatments can cause local skin reactions, and the specific safety profile belongs to the particular product. Soolantra labeling describes possible burning and irritation. Metronidazole products can also produce local discomfort, dryness, redness or irritation, with warnings and contraindications that vary by formulation. A claim that either treatment is entirely nonirritating would be inaccurate, especially for skin already affected by rosacea.
Metronidazole 1% gel labeling includes a contraindication for people with known hypersensitivity to metronidazole or other ingredients of that formulation and precautions regarding certain neurologic findings and blood disorders. These details should be checked against the actual dispensed product rather than generalized indiscriminately across all creams, gels and lotions. Soolantra and metronidazole are for topical use; their labels warn against inappropriate routes such as use in the eyes. If a product causes an unexpected or significant reaction, a clinician or pharmacist can advise on appropriate next steps.
Pregnancy, breastfeeding, pediatric use, allergies and other medicines warrant individualized review. The existence of FDA-approved topical products does not establish their suitability in every circumstance, and a general web comparison should not replace a review of patient-specific risks. When collecting a prescription, ask the pharmacist to explain the product-specific instructions and any precautions relevant to your history.
Both Soolantra and topical metronidazole are prescription products in the United States. A valid prescription identifies the treatment a clinician has chosen, while the pharmacy confirms product details and applicable dispensing requirements. The Soolantra prescription access guide explains the brand-specific pharmacy process; the current page instead compares the two active medicines and the checks needed to avoid confusion between them.
For Soolantra, an appropriately approved generic ivermectin cream 1% may be relevant, subject to the prescription and applicable substitution rules. Metronidazole has its own branded and generic formulations, so a listing for metronidazole cream 0.75% is not the same as a listing for 1% gel. When a prescription specifies an exact dosage form, a different form or active ingredient should not be substituted merely on the basis of a storefront search result. Pharmacists can clarify available products and contact prescribers when a change needs authorization.
For an online pharmacy, verification of the prescription requirement, appropriate U.S. licensure and pharmacist access is separate from whether a particular medicine is in stock. Our online pharmacy verification guide covers seller legitimacy; it does not certify any seller as having Soolantra or metronidazole available. Manufacturer names, a drug’s approval status and an active product record do not themselves constitute a current retail inventory report.
The amount a patient may pay depends on the exact formulation, brand-versus-generic status, package size, pharmacy pricing method and benefit design. Soolantra brand cream and a generic ivermectin cream 1% are not automatically quoted at the same amount, and metronidazole prices cannot be inferred from those ivermectin quotes. Even among metronidazole products, a 0.75% cream and a 1% gel may be processed as different items. A meaningful comparison first matches the exact name, strength, vehicle and quantity on the prescription.
Insurance plans may prefer one product, require prior authorization for a brand or apply different patient cost-sharing rules. Those conditions change across plans and benefit years and cannot be presumed from the medicine’s name alone. The Soolantra insurance guide covers formulary and claim questions in detail, while Soolantra pricing factors focuses on brand-specific quotation issues. This article does not publish live costs or state that a particular insurer covers either treatment.
When requesting quotes, compare like-for-like prescription details and ask whether the figure is for the brand, an approved generic, cash payment or an insurance claim. A coupon headline or advertised online price is not enough to identify the dispensed product or the final amount due. The selection of treatment belongs to the clinician; pharmacy cost questions can inform a follow-up discussion without encouraging an unsupervised medicine switch.
Before a clinician or pharmacist can make the comparison useful for an individual, the practical details must be clear: which rosacea features are being treated, which exact metronidazole formulation is under consideration and whether prior topical products caused irritation or failed to improve inflammatory lesions. The 16-week research result is relevant context, but treatment selection cannot be reduced to that single number. It may also depend on preferred vehicle, labeling directions, insurance and access to follow-up care.
The checklist below is designed for a discussion, not for self-prescribing. If metronidazole is being proposed instead of Soolantra, clarify whether that means 0.75% cream, another 0.75% formulation or 1% gel. If the proposed change is from branded Soolantra to generic ivermectin cream 1%, that is a different brand-to-generic comparison altogether. Other rosacea treatment classes have their own decision points, addressed separately in Soolantra vs azelaic acid and Soolantra vs doxycycline.
| Question for the clinician or pharmacist | What to clarify | Why it matters |
|---|---|---|
| What is the treatment target? | Inflammatory lesions versus predominant redness, flushing or another symptom | Evidence for papules and pustules does not cover every rosacea feature |
| Which metronidazole product? | 0.75% cream, 0.75% gel/lotion or 1% gel | Formulation and label may differ from the trial comparator |
| What was actually studied? | Ivermectin 1% cream once daily vs metronidazole 0.75% cream twice daily | Avoid applying the trial result to unstudied product pairings |
| Any prior response or sensitivity? | History of irritation, allergy or response to previous creams and gels | Personal tolerability can alter the treatment discussion |
| What does the prescription specify? | Ingredient, strength, vehicle, brand/generic and quantity | Reduces dispensing and substitution confusion |
| What if the pharmacy proposes a different product? | Whether pharmacist substitution is allowed or prescriber approval is needed | A different active ingredient is not routine generic substitution |
| How should response be reviewed? | Clinician-directed follow-up and warning signs requiring reassessment | A trial result cannot guarantee an individual response |
| What is the actual pharmacy quote? | Exact product, payment method, plan requirements and supply terms | Prevents assumptions about pricing or stock |
No. Soolantra cream contains ivermectin 1%, while metronidazole is a different active ingredient found in several prescription topical rosacea products. They are treatment alternatives for some inflammatory rosacea presentations, not brand and generic versions of one medicine.
In a 16-week randomized trial involving people with moderate-to-severe papulopustular rosacea, ivermectin 1% cream once daily produced a greater average reduction in inflammatory lesion counts than metronidazole 0.75% cream twice daily. The result applies to the products and population studied and does not guarantee an individual outcome.
No. The widely cited direct trial compared ivermectin 1% cream with metronidazole 0.75% cream. Metronidazole 1% gel is a different formulation with its own labeling, so conclusions from that trial should not automatically be assigned to it.
No. Directions differ by product. Metronidazole 0.75% cream is commonly labeled for twice-daily use, while METROGEL 1% has once-daily labeling. Follow the exact dispensed product’s instructions and the prescriber’s directions.
Yes. Soolantra cream 1% and the topical metronidazole products discussed here are prescription medicines in the United States. An appropriate clinician assessment and a valid prescription are required for pharmacy dispensing.
Metronidazole has a different active ingredient from ivermectin. Changing between them is not an ordinary brand-to-generic substitution and may require a new prescription or prescriber authorization. A pharmacist can review the existing order and applicable requirements.
Soolantra is labeled for inflammatory lesions of rosacea. That does not establish that it treats all rosacea features, such as persistent redness, flushing, visible vessels or eye symptoms. Treatment selection depends on the symptoms and clinical assessment.
Neither medicine is guaranteed to be irritation-free. Local reactions are possible with both, and tolerability can depend on the individual and the exact cream or gel base. Review the product-specific warnings and discuss prior reactions with a clinician.
Not necessarily. Actual out-of-pocket cost depends on the specific branded or generic product, package size, pharmacy, payment method and insurance benefits. A licensed pharmacy can quote the exact prescribed product; broad price claims may be misleading.
No medication change should be based solely on a general comparison. A clinician can review the diagnosis, treatment response, tolerability and specific product before deciding whether a different prescription is appropriate.